We sincerely appreciate the comments by Bruno Halpern and Marcio Mancini about our Personal View on bariatric and metabolic surgery during and after the COVID-19 pandemic.[@bib1] We take this opportunity to clarify the objectives of the Diabetes Surgery Summit (DSS) recommendations regarding the prioritisation of patients who are already candidates for bariatric or metabolic surgery. The authors assert that individuals with diabetes and established cardiovascular disease should be treated with SGLT2 inhibitors or glucagon-like peptide-1 receptor agonists instead of bariatric or metabolic surgery, because the former have been shown in randomised controlled trials to reduce cardiovascular disease, whereas there is less evidence for that with bariatric and metabolic surgery in this population. However, our current treatment algorithm is not designed to help to decide between surgical and pharmaceutical diabetes therapies. Rather, it prioritises the timing of operations among patients who are eligible for surgery and have already decided to undergo it, presumably because medical or lifestyle interventions have proven insufficient.

We heartily agree that a secondary prevention cardiovascular outcomes randomised controlled trial on surgical versus medical treatments for obesity and diabetes is needed, and we are attempting to actualise this. Nevertheless, it is clear that tight glycaemic control reduces diabetes microvascular complications and, in the long term, macrovascular events,[@bib2] as well as that bariatric and metabolic surgery almost universally improves hyperglycaemia, causing diabetes remission in most cases.[@bib3] Thus, it seems highly likely that such operations reduce cardiovascular disease. Numerous excellent observational studies have reported this, and 29 independent investigations have universally found bariatric and metabolic surgery to be associated with reduced mortality among patients with and without established cardiovascular disease.[@bib4] We are aware of evidence currently under review showing impressive reductions in major adverse cardiovascular events after bariatric and metabolic surgery, specifically among patients with pre-existing cardiovascular disease. In a study presented in 2018, bariatric and metabolic surgery has proven to confer significant protective effects on patients who, after surgery, end up having either a heart attack or a stroke. These patients' chances for in-hospital survival are improved, and their hospital length-of-stay after the event is shorter.[@bib5]

According to our recommendations, eligible patients with metabolic disease should be expedited for bariatric and metabolic surgery because there are clear risks of harm if these operations are postponed.

Not long ago, anti-diabetes medications were widely used without any evidence of decreasing cardiovascular disease or mortality. It is undisputed that controlling hyperglycaemia and other metabolic disorders (as typically occurs after bariatric and metabolic surgery) decreases the incidence of major adverse cardiovascular events and mortality. Moreover, there is absolutely no evidence that surgery promotes negative outcomes in major adverse cardiovascular events or mortality.

According to several different guidelines, patients should undergo bariatric and metabolic surgery because they have not reached adequate metabolic control through medical or lifestyle treatment alone. The DSS guidelines, along with several others (eg, American Diabetes Association, European Association for the Study of Diabetes, National Institute for Health and Care Excellence, Brazilian Council of Medicine) are currently conservative with respect to available evidence.[@bib6] Although we acknowledge that a large, multicentre randomised controlled trial with hard cardiovascular endpoints is needed, current guidance is legitimised by 13 unanimous randomised trials and numerous non-randomised studies.[@bib3] Metabolic surgery is highly efficacious, safe, and cost-effective, at least for patients with a BMI of at least 30 kg/m^2^.[@bib7]

In response to Vasileios Charalampakis and colleagues, we agree that confusion could arise because of the differing recommendations from the DSS faculty versus representatives of the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO). We, the former group, prioritise bariatric and metabolic surgery after COVID-19 on the basis of patients' burden of metabolic diseases most likely to cause harm if surgery is delayed, whereas IFSO recommends operating first on the healthiest patients. This is an intellectual disagreement, and we find it curious that IFSO formally endorsed our Personal View, before subsequently publishing their own differing recommendations. In our opinion, individuals with obesity but minimal comorbidities can safely wait for bariatric and metabolic surgery until COVID-19 concerns have largely dissipated---eg, after a vaccine is developed---whereas sicker patients cannot afford to do so. Our guidelines are highly evidence based and consensuated among multidisciplinary authors (75% non-surgeons), as opposed to the IFSO recommendations generated by entirely by surgeons. We recognise that obesity and diabetes increase risks of poor COVID-19 outcomes but counsel that bariatric and metabolic surgery be done with extensive precautions to prevent peri-operative infection with severe acute respiratory syndrome coronavirus 2. The typical benefits of surgery on obesity and diabetes should render patients less vulnerable to severe or critical COVID-19 disease if they acquire it in the community post-operatively.

We fully concur with Melissa Santos and colleagues that a mental health provider should be an integral part of any bariatric and metabolic surgery multidisciplinary team, and that patients' psychosocial characteristics should be considered when prioritising such operations. It would be very difficult, however, to quantify this principle with a discrete criterion in our triaging algorithm. Hence, we did not include it.
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